Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.

Literature DB >> 19040393

Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.

Abstract

RNA interference technology has been developed as a potential therapeutic agent for many indications, including cancer. Silencing a specific oncogene in tumor cells brings about cell death both in vitro and in vivo. However, there is a great need for powerful delivery strategies to enhance the therapeutic effect of small interfering RNA (siRNA). This review summarizes different signaling pathways inhibited by siRNA and the advantages of targeted siRNA as a delivery system.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 19040393 PMCID： PMC5515368 DOI： 10.1517/17425240802568505

Source DB: PubMed Journal: Expert Opin Drug Deliv ISSN： 1742-5247 Impact factor: 6.648

78 in total

1. Cell delivery, intracellular trafficking and expression of an integrin-mediated gene transfer vector in tracheal epithelial cells.

Authors: M Colin; M Maurice; G Trugnan; M Kornprobst; R P Harbottle; A Knight; R G Cooper; A D Miller; J Capeau; C Coutelle; M C Brahimi-Horn
Journal: Gene Ther Date: 2000-01 Impact factor: 5.250

Review 2. Apoptosis-an introduction.

Authors: Alfons Lawen
Journal: Bioessays Date: 2003-09 Impact factor: 4.345

3. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

Authors: Jyotsnabaran Halder; Aparna A Kamat; Charles N Landen; Liz Y Han; Susan K Lutgendorf; Yvonne G Lin; William M Merritt; Nicholas B Jennings; Arturo Chavez-Reyes; Robert L Coleman; David M Gershenson; Rosemarie Schmandt; Steven W Cole; Gabriel Lopez-Berestein; Anil K Sood
Journal: Clin Cancer Res Date: 2006-08-15 Impact factor: 12.531

4. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors: James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal: Nat Biotechnol Date: 2006-06-25 Impact factor: 54.908

Review 5. Small molecule and monoclonal antibody therapies in neurooncology.

Authors: Nicholas Butowski; Susan M Chang
Journal: Cancer Control Date: 2005-04 Impact factor: 3.302

Review 6. The epidermal growth factor receptor pathway: a model for targeted therapy.

Authors: Maurizio Scaltriti; José Baselga
Journal: Clin Cancer Res Date: 2006-09-15 Impact factor: 12.531

7. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology.

Authors: Chun-Fang Xia; Yufeng Zhang; Yun Zhang; Ruben J Boado; William M Pardridge
Journal: Pharm Res Date: 2007-10-11 Impact factor: 4.200

Review 8. New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule.

Authors: Shingo Miyamoto; Hiroshi Yagi; Fusanori Yotsumoto; Shinji Horiuchi; Toshiyuki Yoshizato; Tatsuhiko Kawarabayashi; Masahide Kuroki; Eisuke Mekada
Journal: Anticancer Res Date: 2007 Nov-Dec Impact factor: 2.480

9. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi).

Authors: Christiane Nieth; Axel Priebsch; Alexandra Stege; Hermann Lage
Journal: FEBS Lett Date: 2003-06-19 Impact factor: 4.124

Review 10. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development.

Authors: Frank Y Xie; Martin C Woodle; Patrick Y Lu
Journal: Drug Discov Today Date: 2006-01 Impact factor: 7.851

10 in total

Review 1. Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery.

Authors: Bin Shi; Marc Abrams
Journal: J Histochem Cytochem Date: 2013-03-14 Impact factor: 2.479

2. Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery.

Authors: Bin Shi; Ed Keough; Andrea Matter; Karen Leander; Stephanie Young; Ed Carlini; Alan B Sachs; Weikang Tao; Marc Abrams; Bonnie Howell; Laura Sepp-Lorenzino
Journal: J Histochem Cytochem Date: 2011-08 Impact factor: 2.479

3. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates.

Authors: Yizhou Dong; Kevin T Love; J Robert Dorkin; Sasilada Sirirungruang; Yunlong Zhang; Delai Chen; Roman L Bogorad; Hao Yin; Yi Chen; Arturo J Vegas; Christopher A Alabi; Gaurav Sahay; Karsten T Olejnik; Weiheng Wang; Avi Schroeder; Abigail K R Lytton-Jean; Daniel J Siegwart; Akin Akinc; Carmen Barnes; Scott A Barros; Mary Carioto; Kevin Fitzgerald; Julia Hettinger; Varun Kumar; Tatiana I Novobrantseva; June Qin; William Querbes; Victor Koteliansky; Robert Langer; Daniel G Anderson
Journal: Proc Natl Acad Sci U S A Date: 2014-02-10 Impact factor: 11.205

4. Biological effects of RNAi targeted inhibiting Tiam1 gene expression on cholangiocarcinoma cells.

Authors: Wei Cheng; Yaling Liu; Zhi Zuo; Xinmin Yin; Bo Jiang; Daojin Chen; Chuang Peng; Jianhui Yang
Journal: Int J Clin Exp Pathol Date: 2015-12-01

5. Targeted gene silencing using a follicle-stimulating hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro.

Authors: Shanshan Hong; Xiaoyan Zhang; Jun Chen; Jiabing Zhou; Yufang Zheng; Congjian Xu
Journal: J Ovarian Res Date: 2013-11-20 Impact factor: 4.234